The pseudosolubilized medium-chain-length n-alkanes during biodegradation process, and optimization of medium composition and culture conditions for rhamnolipid production by Pseudomonas sp. DG17 using Plackett-Burman design and Box-Behnken design, were examined in this study. The results showed that pseudosolubilized concentration of C14 to C20 n-alkanes was higher than that of C24 to C26. After incubation for 120 h, pseudosolubilized C16H34 increased to 2.63 ± 0.21 mg. Meanwhile, biodegradation rates of n-alkanes decreased along with the increase of carbon chain length. Carbon-14 assay suggested that nonlabeled C14H30, C16H34, and C20H42 inhibited the biodegradation of (14)C n-octadecane, and Pseudomonas sp. DG17 utilized different alkanes simultaneously. Three significant variables (substrate concentration, salinity, and C/N) that could influence rhamnolipid production were screened by Plackett-Burman design. Results of Box-Behnken design suggested that rhamnolipid concentration could be achieved at 91.24 mg L(-1) (observed value) or 87.92 mg L(-1) (predicted value) with the optimal levels of concentration, salinity, and C/N of 400 mg L(-1), 1.5 %, and 45, respectively.

03 Sep 2014·Biotechnology & Biotechnological EquipmentQ4 · ENGINEERING & TECHNOLOGY

Immobilization ofPseudomonassp. DG17 onto sodium alginate–attapulgite–calcium carbonate

Q4 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Zhao, Yi Cun ; Wang, Xuan ; Li, Yi ; Hua, Fei ; Wang, Hong Qi

A strain of Pseudomonas sp. DG17, capable of degrading crude oil, was immobilized in sodium alginate-attapulgite-calcium carbonate for biodegradation of crude oil contaminated soil. In this work, proportion of independent variables, the laboratory immobilization parameters, the micromorphology and internal structure of the immobilized granule, as well as the crude oil biodegradation by sodium alginate-attapulgite-calcium carbonate immobilized cells and sodium alginate-attapulgite immobilized cells were studied to build the optimal immobilization carrier and granule-forming method. The results showed that the optimal concentrations of sodium alginate-attapulgite-calcium carbonate and calcium chloride were 2.5%-3.5%, 0.5%-1%, 3%-7% and 2%-4%, respectively. Meanwhile, the optimal bath temperature, embedding cell amount, reaction time and multiplication time were 50-60 °C, 2%, 18 h and 48 h, respectively. Moreover, biodegradation was enhanced by immobilized cells with a total petroleum hydrocarbon removal ranging from 33.56% ± 3.84% to 56.82% ± 3.26% after 20 days. The SEM results indicated that adding calcium carbonate was helpful to form internal honeycomb-like pores in the immobilized granules.

01 May 2008·Current HIV ResearchQ4 · MEDICINE

Phase 1 Single Dose Studies to Optimize the Pharmacokinetics of DG17, a Novel HIV-Protease Inhibitor Pro-Drug, Using Sodium Bicarbonate and Ritonavir

Q4 · MEDICINE

Article

Author: John Mills ; Jennifer F. Hoy ; James S. Rowe ; Sharon R. Lewin ; Henry Krum ; Catherine L. Cherry

DG17 is an orally available prodrug of DG35 (a novel HIV protease inhibitor with variable pharmacokinetics). These studies aimed to optimize DG17 pharmacokinetics by gastric acid neutralization and ritonavir pharmacoenhancement. Both studies were conducted using a randomized, cross-over design in which 6 healthy individuals were administered a single dose of 100mg or 200mg DG17, half with the study intervention (sodium bicarbonate solution in the first study, low dose ritonavir in the second). After a one week washout period, each subject was then administered a second dose of DG17, with the study intervention only administered to the other half. Cmax and AUC increases with gastric acid neutralization were greatest in those with the lowest absorption of DG17 alone. All doses were subsequently given with sodium bicarbonate solution in the second study. Low-dose ritonavir co-administration with DG17 increased DG35 C(max) (median 1437 versus 100 ng/ml, p=0.028) and AUC (median 6975 versus 154ng/ml*hr, p=0.028) compared with DG17 without ritonavir. Plasma DG35 exceeded the IC(90) for HIV for > or = 12 hours following a single DG17/ritonavir dose. No significant adverse events occurred. Single dose DG17 is safe and best administered in a manner preventing gastric acid degradation and with low-dose ritonavir.

100 Deals associated with NARDG-35

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	-	ResApp Health Ltd.	-
HIV Infections	Preclinical	BR	New Journey Health Technology Group Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NARDG-35

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation